F-star Therapeutics (NASDAQ:FSTX) Downgraded by LADENBURG THALM/SH SH

LADENBURG THALM/SH SH cut shares of F-star Therapeutics (NASDAQ:FSTXGet Rating) from a buy rating to a neutral rating in a research report released on Thursday morning, The Fly reports.

A number of other research analysts have also weighed in on the stock. HC Wainwright initiated coverage on shares of F-star Therapeutics in a research report on Tuesday, May 17th. They set a buy rating and a $35.00 price target on the stock. William Blair lowered shares of F-star Therapeutics from an outperform rating to a market perform rating in a research report on Thursday. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, F-star Therapeutics presently has a consensus rating of Hold and a consensus target price of $29.50.

F-star Therapeutics stock opened at $6.36 on Thursday. F-star Therapeutics has a 1-year low of $2.07 and a 1-year high of $9.38. The firm has a market capitalization of $137.11 million, a price-to-earnings ratio of -4.13 and a beta of 1.84. The firm’s fifty day moving average price is $3.04 and its two-hundred day moving average price is $3.64. The company has a current ratio of 6.11, a quick ratio of 6.11 and a debt-to-equity ratio of 0.14.

F-star Therapeutics (NASDAQ:FSTXGet Rating) last released its quarterly earnings data on Tuesday, May 10th. The company reported ($0.57) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.06. The business had revenue of $2.55 million during the quarter, compared to the consensus estimate of $2.30 million. On average, research analysts forecast that F-star Therapeutics will post -2.35 EPS for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of FSTX. Envestnet Asset Management Inc. purchased a new stake in F-star Therapeutics during the first quarter worth about $48,000. JPMorgan Chase & Co. increased its holdings in F-star Therapeutics by 152.7% during the first quarter. JPMorgan Chase & Co. now owns 21,335 shares of the company’s stock worth $76,000 after buying an additional 12,891 shares during the last quarter. Goldman Sachs Group Inc. purchased a new stake in F-star Therapeutics during the first quarter worth about $120,000. State Street Corp increased its stake in shares of F-star Therapeutics by 15.6% in the first quarter. State Street Corp now owns 53,150 shares of the company’s stock worth $189,000 after purchasing an additional 7,180 shares in the last quarter. Finally, BlackRock Inc. increased its stake in shares of F-star Therapeutics by 1.6% in the first quarter. BlackRock Inc. now owns 295,947 shares of the company’s stock worth $1,050,000 after purchasing an additional 4,776 shares in the last quarter. Institutional investors and hedge funds own 51.67% of the company’s stock.

About F-star Therapeutics (Get Rating)

F-star Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients.

Featured Articles

The Fly logo

Analyst Recommendations for F-star Therapeutics (NASDAQ:FSTX)

Receive News & Ratings for F-star Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for F-star Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.